SCHEMBL10072340

SCHEMBL10072340

Cc1cc(F)cc(C2(C(F)(F)F)CC(c3ccc(C(=O)NCCO)c4ccccc34)=NO2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
KMT2A Q03164 1/20 0.36
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
GPR52 Q9Y2T5 2/20 0.32
MAPK3 P27361 1/20 0.32
PRF1 P14222 1/20 0.31
PDK2 Q15119 3/20 0.31
HTT P42858 1/20 0.31
HPGD P15428 1/20 0.31
LMNA P02545 1/20 0.31
PDCD1 Q15116 1/20 0.31
CD274 Q9NZQ7 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
METAP2 P50579 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10072325 0.91 GPR52 (0.37) MEN1CACNA1BAPBA1KMT2AGPR52
SCHEMBL871765 0.90 GPR52 (0.37) MEN1CACNA1BAPBA1KMT2AALOX5AP
SCHEMBL869750 0.90 GPR52 (0.35) MEN1CACNA1BAPBA1KMT2AALOX5AP
SCHEMBL10072341 0.89 HPGD (0.31) MEN1KMT2AHPGDCA1CA2
SCHEMBL10072330 0.88 ALOX5AP (0.35) MEN1CACNA1BAPBA1KMT2AALOX5AP
SCHEMBL10072339 0.87 HPGD (0.35) MEN1KMT2APDK2HPGDLMNA
SCHEMBL10072350 0.87 ALOX5AP (0.35) MEN1CACNA1BAPBA1KMT2AALOX5AP
SCHEMBL870701 0.86 KMT2A (0.35) MEN1CACNA1BAPBA1KMT2AALOX5AP
SCHEMBL870579 0.86 MEN1 (0.36) MEN1CACNA1BAPBA1KMT2AALOX5AP
SCHEMBL871002 0.86 KMT2A (0.36) MEN1CACNA1BAPBA1KMT2AALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404649-B2 Isoxazoline oximes as antiparasitic agents AH USA 42 LLC (US) 2013-03-26 US disclosed
US-20120077765-A1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS PFIZER INC. (US) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077765-A1 ISOXAZOLINE OXIMES AS ANTIPARASITIC AGENTS CYP1A2, CYP3A7, CYP2E1 MEN1 3815/4885CACNA1B 2118/4885APBA1 3914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.